Odonate, Inc. Stock price

Equities

ODTC

US6760792050

Pharmaceuticals

Market Closed - OTC Markets 01:51:38 2024-03-28 pm EDT 5-day change 1st Jan Change
3,500 USD +3.24% Intraday chart for Odonate, Inc. +4.48% +16.67%
Sales 2019 - Sales 2020 - Capitalization 740M
Net income 2019 -112M Net income 2020 -126M EV / Sales 2019 -
Net cash position 2019 178M Net cash position 2020 152M EV / Sales 2020 -
P/E ratio 2019
-8.02 x
P/E ratio 2020
-4.99 x
Employees 145
Yield 2019 *
-
Yield 2020
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.24%
1 week+4.48%
Current month+4.48%
1 month+4.48%
3 months+16.67%
6 months+16.67%
Current year+16.67%
More quotes
1 week
3 380.00
Extreme 3380
7 432.00
1 month
3 300.00
Extreme 3300
8 950.00
Current year
2 725.00
Extreme 2725
9 979.00
1 year
2 725.00
Extreme 2725
9 979.00
3 years
1 615.40
Extreme 1615.4
9 979.00
5 years
1 615.40
Extreme 1615.4
92 999.80
10 years
1 615.40
Extreme 1615.4
92 999.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 12-12-31
Director of Finance/CFO 61 14-12-31
Chief Operating Officer - 13-12-31
Members of the board TitleAgeSince
Chief Executive Officer 57 12-12-31
Director/Board Member 62 17-06-30
Director/Board Member 45 16-11-30
More insiders
Date Price Change Volume
24-03-28 3,500 +3.24% 2
24-03-27 3,390 +0.30% 1
24-03-26 3,380 0.00% 1
24-03-25 3,380 +0.90% 32

Delayed Quote OTC Markets, March 28, 2024 at 01:51 pm EDT

More quotes
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Odonate, Inc. - OTC Markets